Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder	Recruiting	Phase 2	2026-06-15		NCT06397911

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Oneness Biotech Co., Ltd.	5

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
California Allergy and Asthma Medical Group	Los Angeles	United States	5
Center for Clinical Studies	Webster	United States	12
Center For Dermatology Clinical Research, Inc.	Fremont	United States	9
China Medical University Hospital	Taichung	Taiwan	54
First Oc Dermatology	Fountain Valley	United States	16
Kaohsiung Chang Gung Memorial Hospital	Kaohsiung City	Taiwan	18
Kaohsiung Veterans General Hospital	Kaohsiung City	Taiwan	15
Linkou Chang Gung Memorial Hospital	New Taipei City	Taiwan	1
National Cheng Kung University Hospital	Tainan	Taiwan	53
National Taiwan University Hospital	Taipei	Taiwan	203
Taipei Mackay Memorial Hospital	Taipei	Taiwan	1
Taipei Medical University-Shuang Ho Hospital	New Taipei City	Taiwan	2
Taipei Veterans General Hospital	Taipei	Taiwan	64
Tri-Service General Hospital	Taipei	Taiwan	27
University of California, Davis Health, Department of Dermatology	Sacramento	United States	1
UT Health Science Houston	Bellaire	United States	1